The Patent Finder
AP

Amryt Pharmaceuticals Inc.

First filing 2002
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Aegerion Pharmaceuticals, Inc. (to 2021)

36 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Dec 2026
Next term end
16
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Pharmaceutical Compositions and Related Methods of Delivery US 11,400,159
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Ends Sep 2029 · Medium confidence
Also notable
Method of Treating Diseases US 11,338,011
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Ends Feb 2036 · Medium confidence
Also notable
Oral Octreotide Administered in Combination with Other Therapeutic Agents US 10,682,387
Cited by 14 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035.
Ends Dec 2035 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 25, 2027
    The maintenance fee for Methods of Detecting Anti-Leptin Neutralizing Antibodies (US 11,709,166) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
  • 1 fee due May 28, 2027
    The maintenance fee for Betulin-Containing Birch Bark Extracts and Their Formulation (US 11,826,374) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Method of Treating Diseases (US 11,857,595) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 2 fees due Aug 6 to 23, 2027 · next Aug 6
  • 1 fee due Oct 30, 2027
    The maintenance fee for Pharmaceutical Compositions and Related Methods of Delivery (US 11,969,471) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,536,380Triterpene-Containing Oleogel-Forming Agent, Triterpene-Containing Oleogel and Method for Producing a Triterpene-Containing Oleogel
In force
 · High confidence
In forceHigh confidence
US 8,241,670Compositions Capable of Facilitating Penetration Across a Biological Barrier
In force
 · High confidence
In forceHigh confidence
US 8,329,198Pharmaceutical Compositions and Related Methods of Delivery
In force
 · Low confidence
In forceLow confidence
US 8,535,695Pharmaceutical Compositions and Related Methods of Delivery
In force
 · Low confidence
In forceLow confidence
US 9,265,812Pharmaceutical Compositions and Related Methods of Delivery
In force
 · Low confidence
In forceLow confidence
US 9,566,246Pharmaceutical Compositions and Related Methods of Delivery
In force
 · Medium confidence
In forceMedium confidence
US 11,400,159Pharmaceutical Compositions and Related Methods of Delivery
In force
 · Medium confidence
In forceMedium confidence
US 11,969,471Pharmaceutical Compositions and Related Methods of Delivery
In force
 · Medium confidence
In forceMedium confidence
US 11,986,529Pharmaceutical Compositions and Related Methods of Delivery
In force
 · Medium confidence
In forceMedium confidence
US 9,352,041Use of an Oleogel Containing Triterpene for Healing Wounds
In force
 · High confidence
In forceHigh confidence
10 of 36 patents shown.
Pro members see all 36.
Pro members: see all 36 patents
Also on record, not counted in the 36: 2 patents ended · 11 applications pending · 11 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited